| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Mario Preti | Q57305779 |
| Massimo Origoni | Q42856910 | ||
| P2093 | author name string | Silvano Costa | |
| Luciano Mariani | |||
| Maria Teresa Sandri | |||
| Paolo Cristoforoni | |||
| Guia Carminati | |||
| Chiara Stefani | |||
| P2860 | cites work | Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing | Q33698073 |
| HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review | Q33762996 | ||
| Triage of women with low-grade cervical lesions--HPV mRNA testing versus repeat cytology | Q34019808 | ||
| Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer | Q34046296 | ||
| HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy | Q34048160 | ||
| The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia | Q34065016 | ||
| Assay formats involving acridinium-ester-labeled DNA probes | Q69522112 | ||
| Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology | Q74447110 | ||
| Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence | Q81195427 | ||
| Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3 | Q84748387 | ||
| Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia | Q34299355 | ||
| HPV mRNA is more specific than HPV DNA in triage of women with minor cervical lesions | Q34535660 | ||
| Characteristics and applications of nucleic acid sequence-based amplification (NASBA). | Q34551050 | ||
| Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test | Q35140046 | ||
| The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. | Q35692254 | ||
| The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review | Q35984769 | ||
| High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology | Q36118590 | ||
| Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia | Q36311966 | ||
| HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. | Q36708180 | ||
| 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests | Q36955449 | ||
| Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate | Q37294687 | ||
| Management of atypical squamous cells, low-grade squamous intraepithelial lesions, and cervical intraepithelial neoplasia 1. | Q37343099 | ||
| Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. | Q37451826 | ||
| The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy | Q38011639 | ||
| Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types | Q38123772 | ||
| The human papillomavirus family and its role in carcinogenesis | Q38169482 | ||
| E6/E7 mRNA expression analysis: a test for the objective assessment of cervical adenocarcinoma in clinical prognostic procedure. | Q38344431 | ||
| Role of E6/E7 mRNA test in the diagnostic algorithm of HPV-positive patients showing ASCUS and LSIL: clinical and economic implications in a publicly financed healthcare system | Q39124983 | ||
| Performance of HPV E6/E7 mRNA RT-qPCR for screening and diagnosis of cervical cancer with ThinPrep Pap test samples | Q42201346 | ||
| Comparison of the performance of the NucliSENS EasyQ HPV E6/E7 mRNA assay and HPV DNA chip for testing squamous cell lesions of the uterine cervix | Q42216983 | ||
| Assessment of HPV-mRNA test to predict recurrent disease in patients previously treated for CIN 2/3. | Q42233345 | ||
| Use of the NucliSENS EasyQ HPV assay in the management of cervical intraepithelial neoplasia | Q42252306 | ||
| E6/E7 mRNA expression of high-risk HPV types in 849 Greek women. | Q42270719 | ||
| Diagnostic accuracy of guided cervical biopsies: a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen | Q43884166 | ||
| Immediate colposcopy referral in women with low-grade abnormal results on cervical cytology detects more CIN2 or worse lesions than cytological surveillance in primary care, but might lead to overtreatment | Q43979517 | ||
| Human papillomavirus (HPV) E6/E7 mRNA as a triage test after detection of HPV 16 and HPV 18 DNA. | Q44413201 | ||
| Women >or=30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: should we reconsider HPV triage for LSIL in older women? | Q44665218 | ||
| European guidelines for clinical management of abnormal cervical cytology, part 2. | Q44728359 | ||
| Detection of residual/recurrent cervical disease after successful LEEP conization: the possible role of mRNA-HPV test | Q44868740 | ||
| 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. | Q46027527 | ||
| Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study). | Q46136299 | ||
| Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment | Q46517601 | ||
| Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization | Q47721285 | ||
| Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. | Q50676894 | ||
| NucliSENS EasyQ HPV v1 test - Testing for oncogenic activity of human papillomaviruses. | Q50734604 | ||
| The diagnostic accuracy of two methods for E6&7 mRNA detection in women with minor cytological abnormalities. | Q50952735 | ||
| Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. | Q51036686 | ||
| Human papillomavirus E6/E7 mRNA testing has higher specificity than liquid-based DNA testing in the evaluation of cervical intraepithelial neoplasia. | Q53270280 | ||
| Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. | Q54402491 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | human papilloma virus | Q69999790 |
| P304 | page(s) | 533 | |
| P577 | publication date | 2015-04-29 | |
| P1433 | published in | Ecancermedicalscience | Q27722239 |
| P1476 | title | E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective | |
| P478 | volume | 9 |
| Q90076035 | Advanced in developmental organic and inorganic nanomaterial: a review |
| Q40228937 | Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease |
| Q38674506 | Concordance of HPV load and HPV mRNA for 16 carcinogenic/possibly carcinogenic HPV types in paired smear/tissue cervical cancer specimens. |
| Q40744991 | Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study. |
| Q47566800 | Negative Pap tests in women with high-grade cervical lesions on follow-up biopsies: Contributing factors and role of human papillomavirus genotyping |
| Q48336018 | Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer |
| Q60907824 | Quantification of HPV16 E6/E7 mRNA Spliced Isoforms Viral Load as a Novel Diagnostic Tool for Improving Cervical Cancer Screening |
| Q90183581 | RNA-based high-risk HPV genotyping and identification of high-risk HPV transcriptional activity in cervical tissues |
| Q92256596 | The potential of RNA as a target for national screening of pre-cancer |
| Q38824019 | Triage of high-risk HPV positive women in cervical cancer screening. |
Search more.